POSTPONED - CRM External Seminar: Professor Kamil Kranc, Deputy Centre Lead, Centre for Haemato-Oncology, Barts Cancer Institute, UK Professor Kamil Kranc Centre for Haemato-Oncology Barts Cancer Institute, Barts Cancer Institute Contact details Email: kamil.kranc@qmul.ac.uk Postponed - to be rescheduled Talk title Targeting RNA modifications and hypoxia signalling pathways to eliminate cancer stem cells in acute myeloid leukaemia Host Donal O'Carroll Abstract Acute myeloid leukaemia (AML) is an aggressive disorder of haematopoietic stem and progenitor cells (HSCs), which acquire driver mutations to generate treatment-resistant leukaemic stem cells (LSCs). LSCs fuel leukaemic disease, which damages the bone marrow and spreads to multiple organs, resulting in a widespread tissue devastation. Current AML therapies are toxic to normal haematopoiesis, and, moreover, often fail to eliminate LSCs. The surviving population of LSCs drives minimal residual disease, ultimately causing fatal disease relapses. Given the sobering survival outcomes of AML, it is critical to identify new therapeutic targets that potently and selectively eliminate LSCs, while protecting normal tissue function. During Kamil's seminar, he will present recent studies discovering novel therapeutic targets for selective LSC elimination. These investigations revealed that inactivation of several key regulators of mRNA modifications and the hypoxia sensing pathway compromises LSCs in AML, while enhancing HSC function. Kamil will show genetic dissection and functional validation of these targets as well as mechanistic insights, and advances in drug discovery to pave the way towards their clinical translation. Bio Kamil Kranc is a full Professor of Haematology and Deputy Lead of the Centre for Haemato-Oncology at Barts Cancer Institute in London. The central aim of Kamil’s laboratory is to understand the biology of leukaemic stem cells and identify therapeutic targets to specifically eradicate them, thus discovering novel and efficient therapies. His laboratory also focuses on understanding haematopoietic stem cell biology with the hope to harness this knowledge to expand these stem cells for therapeutic purposes. Kamil's current research focuses on the significance of RNA modifications and hypoxia pathways in normal and malignant haematopoiesis. Kamil completed his medical degree in Poland (1994-2000), a DPhil (PhD) in Biochemistry at the University of Oxford (2000-2003) and postdoctoral training in immunology and stem cell biology also in Oxford (2003-2007). He was a group leader at Oxford (2007-2010) and Glasgow (2010-2013), before becoming a Professor and a CRUK Senior Fellow at the University of Edinburgh (2013-2018). In 2018, he was appointed Professor of Haematology at Barts Cancer Institute. Nov 23 2023 12.00 - 13.00 POSTPONED - CRM External Seminar: Professor Kamil Kranc, Deputy Centre Lead, Centre for Haemato-Oncology, Barts Cancer Institute, UK POSTPONED - Professor Kamil Kranc, Centre for Haemato-Oncology, Barts Cancer Institute This event is a Centre for Regenerative Medicine (CRM) external seminar which will take place in the seminar room, 1st floor, IRR North. Where to find us
POSTPONED - CRM External Seminar: Professor Kamil Kranc, Deputy Centre Lead, Centre for Haemato-Oncology, Barts Cancer Institute, UK Professor Kamil Kranc Centre for Haemato-Oncology Barts Cancer Institute, Barts Cancer Institute Contact details Email: kamil.kranc@qmul.ac.uk Postponed - to be rescheduled Talk title Targeting RNA modifications and hypoxia signalling pathways to eliminate cancer stem cells in acute myeloid leukaemia Host Donal O'Carroll Abstract Acute myeloid leukaemia (AML) is an aggressive disorder of haematopoietic stem and progenitor cells (HSCs), which acquire driver mutations to generate treatment-resistant leukaemic stem cells (LSCs). LSCs fuel leukaemic disease, which damages the bone marrow and spreads to multiple organs, resulting in a widespread tissue devastation. Current AML therapies are toxic to normal haematopoiesis, and, moreover, often fail to eliminate LSCs. The surviving population of LSCs drives minimal residual disease, ultimately causing fatal disease relapses. Given the sobering survival outcomes of AML, it is critical to identify new therapeutic targets that potently and selectively eliminate LSCs, while protecting normal tissue function. During Kamil's seminar, he will present recent studies discovering novel therapeutic targets for selective LSC elimination. These investigations revealed that inactivation of several key regulators of mRNA modifications and the hypoxia sensing pathway compromises LSCs in AML, while enhancing HSC function. Kamil will show genetic dissection and functional validation of these targets as well as mechanistic insights, and advances in drug discovery to pave the way towards their clinical translation. Bio Kamil Kranc is a full Professor of Haematology and Deputy Lead of the Centre for Haemato-Oncology at Barts Cancer Institute in London. The central aim of Kamil’s laboratory is to understand the biology of leukaemic stem cells and identify therapeutic targets to specifically eradicate them, thus discovering novel and efficient therapies. His laboratory also focuses on understanding haematopoietic stem cell biology with the hope to harness this knowledge to expand these stem cells for therapeutic purposes. Kamil's current research focuses on the significance of RNA modifications and hypoxia pathways in normal and malignant haematopoiesis. Kamil completed his medical degree in Poland (1994-2000), a DPhil (PhD) in Biochemistry at the University of Oxford (2000-2003) and postdoctoral training in immunology and stem cell biology also in Oxford (2003-2007). He was a group leader at Oxford (2007-2010) and Glasgow (2010-2013), before becoming a Professor and a CRUK Senior Fellow at the University of Edinburgh (2013-2018). In 2018, he was appointed Professor of Haematology at Barts Cancer Institute. Nov 23 2023 12.00 - 13.00 POSTPONED - CRM External Seminar: Professor Kamil Kranc, Deputy Centre Lead, Centre for Haemato-Oncology, Barts Cancer Institute, UK POSTPONED - Professor Kamil Kranc, Centre for Haemato-Oncology, Barts Cancer Institute This event is a Centre for Regenerative Medicine (CRM) external seminar which will take place in the seminar room, 1st floor, IRR North. Where to find us
Nov 23 2023 12.00 - 13.00 POSTPONED - CRM External Seminar: Professor Kamil Kranc, Deputy Centre Lead, Centre for Haemato-Oncology, Barts Cancer Institute, UK POSTPONED - Professor Kamil Kranc, Centre for Haemato-Oncology, Barts Cancer Institute
